263 related articles for article (PubMed ID: 15229230)
1. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity.
Lichtman AH; Leung D; Shelton CC; Saghatelian A; Hardouin C; Boger DL; Cravatt BF
J Pharmacol Exp Ther; 2004 Nov; 311(2):441-8. PubMed ID: 15229230
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo.
Lichtman AH; Hawkins EG; Griffin G; Cravatt BF
J Pharmacol Exp Ther; 2002 Jul; 302(1):73-9. PubMed ID: 12065702
[TBL] [Abstract][Full Text] [Related]
3. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.
Bisogno T; Melck D; De Petrocellis L; Bobrov MYu ; Gretskaya NM; Bezuglov VV; Sitachitta N; Gerwick WH; Di Marzo V
Biochem Biophys Res Commun; 1998 Jul; 248(3):515-22. PubMed ID: 9703957
[TBL] [Abstract][Full Text] [Related]
4. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
5. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia.
Lichtman AH; Shelton CC; Advani T; Cravatt BF
Pain; 2004 Jun; 109(3):319-327. PubMed ID: 15157693
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid amide hydrolase inhibition by neurotoxic organophosphorus pesticides.
Quistad GB; Sparks SE; Casida JE
Toxicol Appl Pharmacol; 2001 May; 173(1):48-55. PubMed ID: 11350214
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task.
Varvel SA; Wise LE; Niyuhire F; Cravatt BF; Lichtman AH
Neuropsychopharmacology; 2007 May; 32(5):1032-41. PubMed ID: 17047668
[TBL] [Abstract][Full Text] [Related]
9. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
10. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
Ahn K; Johnson DS; Fitzgerald LR; Liimatta M; Arendse A; Stevenson T; Lund ET; Nugent RA; Nomanbhoy TK; Alexander JP; Cravatt BF
Biochemistry; 2007 Nov; 46(45):13019-30. PubMed ID: 17949010
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).
Lodola A; Castelli R; Mor M; Rivara S
Expert Opin Ther Pat; 2015; 25(11):1247-66. PubMed ID: 26413912
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse.
Palmer JA; Higuera ES; Chang L; Chaplan SR
Neuroscience; 2008 Jul; 154(4):1554-61. PubMed ID: 18541380
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.
Dickason-Chesterfield AK; Kidd SR; Moore SA; Schaus JM; Liu B; Nomikos GG; Felder CC
Cell Mol Neurobiol; 2006; 26(4-6):407-23. PubMed ID: 16736384
[TBL] [Abstract][Full Text] [Related]
14. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system.
Cravatt BF; Lichtman AH
Curr Opin Chem Biol; 2003 Aug; 7(4):469-75. PubMed ID: 12941421
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide.
Fowler CJ; Jonsson KO; Tiger G
Biochem Pharmacol; 2001 Sep; 62(5):517-26. PubMed ID: 11585048
[TBL] [Abstract][Full Text] [Related]
16. A second fatty acid amide hydrolase with variable distribution among placental mammals.
Wei BQ; Mikkelsen TS; McKinney MK; Lander ES; Cravatt BF
J Biol Chem; 2006 Dec; 281(48):36569-78. PubMed ID: 17015445
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain.
Glaser ST; Gatley SJ; Gifford AN
J Pharmacol Exp Ther; 2006 Mar; 316(3):1088-97. PubMed ID: 16278311
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms.
Chang L; Luo L; Palmer JA; Sutton S; Wilson SJ; Barbier AJ; Breitenbucher JG; Chaplan SR; Webb M
Br J Pharmacol; 2006 May; 148(1):102-13. PubMed ID: 16501580
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics.
Boger DL; Miyauchi H; Du W; Hardouin C; Fecik RA; Cheng H; Hwang I; Hedrick MP; Leung D; Acevedo O; Guimarães CR; Jorgensen WL; Cravatt BF
J Med Chem; 2005 Mar; 48(6):1849-56. PubMed ID: 15771430
[TBL] [Abstract][Full Text] [Related]
20. Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats.
Panlilio LV; Thorndike EB; Nikas SP; Alapafuja SO; Bandiera T; Cravatt BF; Makriyannis A; Piomelli D; Goldberg SR; Justinova Z
Psychopharmacology (Berl); 2016 May; 233(10):1879-88. PubMed ID: 26558620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
